Copyright
©The Author(s) 2005.
World J Gastroenterol. Jul 21, 2005; 11(27): 4241-4245
Published online Jul 21, 2005. doi: 10.3748/wjg.v11.i27.4241
Published online Jul 21, 2005. doi: 10.3748/wjg.v11.i27.4241
Table 4 Comparison of clinical characteristics and virological features between 48 CHC patients with and without sustained clearance of SENV-D after combination therapy
| SENV-D response | P | ||
| NR (n = 21) | SVR (n = 27) | ||
| Sex (male) (%) | 15 (71.4) | 13 (48.2) | NS |
| Age (yr) | 48.3 ± 10.6 | 51.7 ± 10.3 | NS |
| Serum ALT (IU/L) | 157.6 ± 122.9 | 152.4 ± 216.3 | NS |
| High HCV RNA level | 9 (42.9) | 18 (66.7) | NS |
| (≥ 200000 IU/mL) (%) | |||
| HCV genotype 1b (%) | 7 (33.3) | 12 (44.4) | NS |
| SENV-D ETVR (%) | 13 (61.9) | 24 (88.9) | 0.04 |
| HCV SVR (%) | 17 (81.0) | 18 (66.7) | NS |
- Citation: Dai CY, Chuang WL, Chang WY, Chen SC, Lee LP, Hsieh MY, Hou NJ, Lin ZY, Hsieh MY, Wang LY, Yu ML. Co-infection of SENV-D among chronic hepatitis C patients treated with combination therapy with high-dose interferon-alfa and ribavirin. World J Gastroenterol 2005; 11(27): 4241-4245
- URL: https://www.wjgnet.com/1007-9327/full/v11/i27/4241.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i27.4241